{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:46:48Z","timestamp":1791877608708,"version":"4.3.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"DOI":"10.1007\/s11095-026-04221-1","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:49:10Z","timestamp":1791830950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Screening of Unexplored FDA-approved Inactive Ingredients as Stabilizers for Monoclonal Antibody Products"],"prefix":"10.1007","author":[{"given":"Divya","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charu","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5913-4244","authenticated-orcid":false,"given":"Anurag S.","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"4221_CR1","doi-asserted-by":"publisher","first-page":"2297450","DOI":"10.1080\/19420862.2023.2297450","volume":"16","author":"S Crescioli","year":"2024","unstructured":"Crescioli S, et al. Antibodies to watch in 2024. MAbs. 2024;16:2297450. https:\/\/doi.org\/10.1080\/19420862.2023.2297450.","journal-title":"MAbs"},{"key":"4221_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMra043186","volume":"357","author":"CA Hudis","year":"2007","unstructured":"Hudis CA. Trastuzumab\u2013mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39\u201351. https:\/\/doi.org\/10.1056\/NEJMra043186.","journal-title":"N Engl J Med"},{"key":"4221_CR3","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.xphs.2021.11.024","volume":"111","author":"S Gupta","year":"2022","unstructured":"Gupta S, Jiskoot W, Sch\u00f6neich C, Rathore AS. Oxidation and deamidation of monoclonal antibody products: Potential impact on stability, biological activity, and efficacy. J Pharm Sci. 2022;111:903\u201318. https:\/\/doi.org\/10.1016\/j.xphs.2021.11.024.","journal-title":"J Pharm Sci"},{"key":"4221_CR4","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ejps.2014.05.014","volume":"62","author":"A Fincke","year":"2014","unstructured":"Fincke A, Winter J, Bunte T, Olbrich C. Thermally induced degradation pathways of three different antibody-based drug development candidates. Eur J Pharm Sci. 2014;62:148\u201360. https:\/\/doi.org\/10.1016\/j.ejps.2014.05.014.","journal-title":"Eur J Pharm Sci"},{"key":"4221_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.copbio.2019.01.014","volume":"60","author":"ME Krause","year":"2019","unstructured":"Krause ME, Sahin E. Chemical and physical instabilities in manufacturing and storage of therapeutic proteins. Curr Opin Biotechnol. 2019;60:159\u201367. https:\/\/doi.org\/10.1016\/j.copbio.2019.01.014.","journal-title":"Curr Opin Biotechnol"},{"key":"4221_CR6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.xphs.2019.08.009","volume":"109","author":"Y Le Basle","year":"2020","unstructured":"Le Basle Y, et al. Physicochemical stability of monoclonal antibodies: a review. J Pharm Sci. 2020;109:169\u201390. https:\/\/doi.org\/10.1016\/j.xphs.2019.08.009.","journal-title":"J Pharm Sci"},{"key":"4221_CR7","doi-asserted-by":"publisher","unstructured":"Bas TG. Formulation of recombinant therapeutic proteins: technological innovation, regulations, and evolution towards buffer-free formulations, pharmaceutics. 2025;17. https:\/\/doi.org\/10.3390\/pharmaceutics17091183.","DOI":"10.3390\/pharmaceutics17091183"},{"key":"4221_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-020-02919-4","volume":"37","author":"VA Rao","year":"2020","unstructured":"Rao VA, et al. A comprehensive scientific survey of excipients used in currently marketed, therapeutic biological drug products. Pharm Res. 2020;37:200. https:\/\/doi.org\/10.1007\/s11095-020-02919-4.","journal-title":"Pharm Res"},{"key":"4221_CR9","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1016\/j.xphs.2021.03.017","volume":"110","author":"RG Strickley","year":"2021","unstructured":"Strickley RG, Lambert WJ. A review of formulations of commercially available antibodies. J Pharm Sci. 2021;110:2590-2608.e56. https:\/\/doi.org\/10.1016\/j.xphs.2021.03.017.","journal-title":"J Pharm Sci"},{"key":"4221_CR10","unstructured":"Babu Medi RC. Akhilesh Bhambhani, Excipient selection in biologics and vaccines formulation development, European Pharmaceutical Review. 2014;19:16-20."},{"key":"4221_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.5731\/pdajpst.2011.00634","volume":"65","author":"S Nema","year":"2011","unstructured":"Nema S, Brendel RJ. Excipients and their role in approved injectable products: current usage and future directions. PDA J Pharm Sci Technol. 2011;65:287\u2013332. https:\/\/doi.org\/10.5731\/pdajpst.2011.00634.","journal-title":"PDA J Pharm Sci Technol"},{"key":"4221_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.5530\/ijpi.20251676","volume":"15","author":"S Makkad","year":"2025","unstructured":"Makkad S, Sheikh M, Shende S, Jirvankar P. Pharmaceutical excipients: functions, selection criteria, and emerging trends. Int J Pharm Investig. 2025;15:361\u201376. https:\/\/doi.org\/10.5530\/ijpi.20251676.","journal-title":"Int J Pharm Investig"},{"key":"4221_CR13","volume":"9","author":"J Saito","year":"2022","unstructured":"Saito J, et al. The current states, challenges, ongoing efforts, and future perspectives of pharmaceutical excipients in pediatric patients in each country and region. Children (Basel). 2022;9:453.","journal-title":"Children (Basel)"},{"key":"4221_CR14","unstructured":"Drugs FCfDEaROoG. Inactive Ingredient Search for Approved Drug Products. [cited 2024 1\u201330 September]; Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/iig\/index.cfm."},{"key":"4221_CR15","doi-asserted-by":"publisher","unstructured":"Zhang Y, Williams Iii RO, Tucker HO. Formulation strategies in immunotherapeutic pharmaceutical products, World J Clin Oncol. 2020;11:275\u2013282. https:\/\/doi.org\/10.5306\/wjco.v11.i5.275.","DOI":"10.5306\/wjco.v11.i5.275"},{"key":"4221_CR16","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/jps.22812","volume":"101","author":"A Hawe","year":"2012","unstructured":"Hawe A, et al. Forced degradation of therapeutic proteins. J Pharm Sci. 2012;101:895\u2013913. https:\/\/doi.org\/10.1002\/jps.22812.","journal-title":"J Pharm Sci"},{"key":"4221_CR17","doi-asserted-by":"publisher","unstructured":"Nowak C, et al. Forced degradation of recombinant monoclonal antibodies: a practical guide, MAbs. 2017;9. https:\/\/doi.org\/10.1080\/19420862.2017.1368602.","DOI":"10.1080\/19420862.2017.1368602"},{"key":"4221_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/427235","volume":"2015","author":"CA L\u00f3pez-Morales","year":"2015","unstructured":"L\u00f3pez-Morales CA, et al. Physicochemical and biological characterization of a biosimilar trastuzumab. Biomed Res Int. 2015;2015:427235. https:\/\/doi.org\/10.1155\/2015\/427235.","journal-title":"Biomed Res Int"},{"key":"4221_CR19","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.xphs.2024.12.017","volume":"114","author":"D Sarin","year":"2025","unstructured":"Sarin D, et al. Higher concentration of trehalose dihydrate stabilizes recombinant IgG1 under forced stress conditions. J Pharm Sci. 2025;114:1398\u2013409. https:\/\/doi.org\/10.1016\/j.xphs.2024.12.017.","journal-title":"J Pharm Sci"},{"key":"4221_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-56361-4","author":"D Agrawal","year":"2026","unstructured":"Agrawal D, et al. Bioinformatic pipeline to identify potential therapeutic targets with subsequent isolation and characterization of novel human anti- DDR1 antibodies. Sci Rep. 2026. https:\/\/doi.org\/10.1038\/s41598-026-56361-4.","journal-title":"Sci Rep"},{"key":"4221_CR21","doi-asserted-by":"publisher","unstructured":"Agrawal D, et al. A multitechnique spectroscopy platform for monitoring heterogeneities in the higher-order structure of mAb therapeutics, molecular pharmaceutics. 2026. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5c01948.","DOI":"10.1021\/acs.molpharmaceut.5c01948"},{"key":"4221_CR22","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.3c01157","author":"D Sarin","year":"2024","unstructured":"Sarin D, et al. Impact of excipient extraction and buffer exchange on recombinant monoclonal antibody stability. Mol Pharm. 2024. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c01157.","journal-title":"Mol Pharm"},{"key":"4221_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1208\/s12248-024-00893-y","volume":"26","author":"S Sreenivasan","year":"2024","unstructured":"Sreenivasan S, Rathore AS. Taurine, a naturally occurring amino acid, as a physical stability enhancer of different monoclonal antibodies. AAPS J. 2024;26:25. https:\/\/doi.org\/10.1208\/s12248-024-00893-y.","journal-title":"AAPS J"},{"key":"4221_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1208\/s12249-021-02183-8","volume":"23","author":"PP Bhojane","year":"2021","unstructured":"Bhojane PP, Joshi S, Sahoo SJ, Rathore AS. Unexplored excipients in biotherapeutic formulations: natural osmolytes as potential stabilizers against thermally induced aggregation of IgG1 biotherapeutics. AAPS PharmSciTech. 2021;23:26. https:\/\/doi.org\/10.1208\/s12249-021-02183-8.","journal-title":"AAPS PharmSciTech"},{"key":"4221_CR25","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1002\/jps.21190","volume":"97","author":"BA Kerwin","year":"2008","unstructured":"Kerwin BA. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways. J Pharm Sci. 2008;97:2924\u201335. https:\/\/doi.org\/10.1002\/jps.21190.","journal-title":"J Pharm Sci"},{"key":"4221_CR26","doi-asserted-by":"publisher","first-page":"6614","DOI":"10.1021\/jp911706q","volume":"114","author":"N Chennamsetty","year":"2010","unstructured":"Chennamsetty N, et al. Prediction of aggregation prone regions of therapeutic proteins. J Phys Chem B. 2010;114:6614\u201324. https:\/\/doi.org\/10.1021\/jp911706q.","journal-title":"J Phys Chem B"},{"key":"4221_CR27","doi-asserted-by":"publisher","unstructured":"Barata TS, et al. Identification of protein-excipient interaction hotspots using computational approaches. Int J Mol Sci. 2016;17. https:\/\/doi.org\/10.3390\/ijms17060853.","DOI":"10.3390\/ijms17060853"},{"key":"4221_CR28","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1021\/acs.molpharmaceut.0c00775","volume":"17","author":"S Jo","year":"2020","unstructured":"Jo S, et al. Computational characterization of antibody-excipient interactions for rational excipient selection using the site identification by ligand competitive saturation-biologics approach. Mol Pharm. 2020;17:4323\u201333. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00775.","journal-title":"Mol Pharm"},{"key":"4221_CR29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ejps.2009.06.001","volume":"38","author":"A Hawe","year":"2009","unstructured":"Hawe A, Kasper JC, Friess W, Jiskoot W. Structural properties of monoclonal antibody aggregates induced by freeze\u2013thawing and thermal stress. Eur J Pharm Sci. 2009;38:79\u201387. https:\/\/doi.org\/10.1016\/j.ejps.2009.06.001.","journal-title":"Eur J Pharm Sci"},{"key":"4221_CR30","doi-asserted-by":"publisher","first-page":"25118","DOI":"10.1074\/jbc.M110.160457","volume":"286","author":"MK Joubert","year":"2011","unstructured":"Joubert MK, et al. Classification and characterization of therapeutic antibody aggregates. J Biol Chem. 2011;286:25118\u201333. https:\/\/doi.org\/10.1074\/jbc.M110.160457.","journal-title":"J Biol Chem"},{"key":"4221_CR31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40259-020-00404-3","volume":"34","author":"S Joshi","year":"2020","unstructured":"Joshi S, Rathore AS. Assessment of structural and functional comparability of biosimilar products: trastuzumab as a case study. BioDrugs. 2020;34:209\u201323. https:\/\/doi.org\/10.1007\/s40259-020-00404-3.","journal-title":"BioDrugs"},{"key":"4221_CR32","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ijpharm.2012.06.063","volume":"436","author":"M Paul","year":"2012","unstructured":"Paul M, Vieillard V, Jaccoulet E, Astier A. Long-term stability of diluted solutions of the monoclonal antibody rituximab. Int J Pharm. 2012;436:282\u201390. https:\/\/doi.org\/10.1016\/j.ijpharm.2012.06.063.","journal-title":"Int J Pharm"},{"key":"4221_CR33","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/biot.201400052","volume":"9","author":"V Joshi","year":"2014","unstructured":"Joshi V, et al. Avoiding antibody aggregation during processing: Establishing hold times. Biotechnol J. 2014;9:1195\u2013205. https:\/\/doi.org\/10.1002\/biot.201400052.","journal-title":"Biotechnol J"},{"key":"4221_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1080\/10826068.2012.654572","volume":"42","author":"Z Xu","year":"2012","unstructured":"Xu Z, Li J, Zhou JX. Process development for robust removal of aggregates using cation exchange chromatograhy in monoclonal antibody purification with implementation of quality by design. Prep Biochem Biotechnol. 2012;42:183\u2013202. https:\/\/doi.org\/10.1080\/10826068.2012.654572.","journal-title":"Prep Biochem Biotechnol"},{"key":"4221_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.chroma.2014.06.037","volume":"1356","author":"J Guo","year":"2014","unstructured":"Guo J, Zhang S, Carta G. Unfolding and aggregation of a glycosylated monoclonal antibody on a cation exchange column. Part I. Chromatographic elution and batch adsorption behavior. J Chromatogr A. 2014;1356:117\u201328. https:\/\/doi.org\/10.1016\/j.chroma.2014.06.037.","journal-title":"J Chromatogr A"},{"key":"4221_CR36","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ijpharm.2016.06.038","volume":"510","author":"T Lipi\u00e4inen","year":"2016","unstructured":"Lipi\u00e4inen T, Peltoniemi M, R\u00e4ikk\u00f6nen H, Juppo A. Spray-dried amorphous isomalt and melibiose, two potential protein-stabilizing excipients. Int J Pharm. 2016;510:311\u201322. https:\/\/doi.org\/10.1016\/j.ijpharm.2016.06.038.","journal-title":"Int J Pharm"},{"key":"4221_CR37","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ijpharm.2018.01.015","volume":"538","author":"AK Tuderman","year":"2018","unstructured":"Tuderman AK, Strachan CJ, Juppo AM. Isomalt and its diastereomer mixtures as stabilizing excipients with freeze-dried lactate dehydrogenase. Int J Pharm. 2018;538:287\u201395. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.01.015.","journal-title":"Int J Pharm"},{"key":"4221_CR38","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/pr.2016.97","volume":"80","author":"DL Phelps","year":"2016","unstructured":"Phelps DL, et al. Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants. Pediatr Res. 2016;80:209\u201317. https:\/\/doi.org\/10.1038\/pr.2016.97.","journal-title":"Pediatr Res"},{"key":"4221_CR39","unstructured":"Chow MYT, Lam JKW. Comparing protein stabilisation effects of inositol to mannitol and trehalose in inhalable particles prepared by nano spray-drying. Drug Deliv Lungs. 2023;34:373-6."},{"key":"4221_CR40","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.76923","volume":"11","author":"E Serebryany","year":"2022","unstructured":"Serebryany E, et al. A native chemical chaperone in the human eye lens. Elife. 2022;11:e76923. https:\/\/doi.org\/10.7554\/eLife.76923.","journal-title":"Elife"},{"key":"4221_CR41","doi-asserted-by":"publisher","first-page":"11288","DOI":"10.1021\/acs.iecr.2c01898","volume":"61","author":"M Marchel","year":"2022","unstructured":"Marchel M, Cie\u015bli\u0144ski H, Boczkaj G. Thermal instability of choline chloride-based deep eutectic solvents and its influence on their toxicity\u2500important limitations of DESs as sustainable materials. Ind Eng Chem Res. 2022;61:11288\u2013300. https:\/\/doi.org\/10.1021\/acs.iecr.2c01898.","journal-title":"Ind Eng Chem Res"},{"key":"4221_CR42","doi-asserted-by":"publisher","first-page":"10622","DOI":"10.1039\/C8CC06397D","volume":"54","author":"M Reslan","year":"2018","unstructured":"Reslan M, Ranganathan V, Macfarlane DR, Kayser V. Choline ionic liquid enhances the stability of Herceptin\u00ae (trastuzumab). Chem Commun (Camb). 2018;54:10622\u20135. https:\/\/doi.org\/10.1039\/C8CC06397D.","journal-title":"Chem Commun (Camb)"},{"key":"4221_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/antib5030019","author":"W Li","year":"2016","unstructured":"Li W, et al. Antibody aggregation: insights from sequence and structure. Antibodies. 2016. https:\/\/doi.org\/10.3390\/antib5030019.","journal-title":"Antibodies"},{"key":"4221_CR44","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.bpc.2014.12.003","volume":"197","author":"L Nicoud","year":"2015","unstructured":"Nicoud L, et al. Effect of polyol sugars on the stabilization of monoclonal antibodies. Biophys Chem. 2015;197:40\u20136. https:\/\/doi.org\/10.1016\/j.bpc.2014.12.003.","journal-title":"Biophys Chem"},{"key":"4221_CR45","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/s0006-3495(85)83932-1","volume":"47","author":"T Arakawa","year":"1985","unstructured":"Arakawa T, Timasheff SN. The stabilization of proteins by osmolytes. Biophys J. 1985;47:411\u20134. https:\/\/doi.org\/10.1016\/s0006-3495(85)83932-1.","journal-title":"Biophys J"},{"key":"4221_CR46","doi-asserted-by":"publisher","first-page":"9721","DOI":"10.1073\/pnas.122225399","volume":"99","author":"SN Timasheff","year":"2002","unstructured":"Timasheff SN. Protein-solvent preferential interactions, protein hydration, and the modulation of biochemical reactions by solvent components. Proc Natl Acad Sci U S A. 2002;99:9721\u20136. https:\/\/doi.org\/10.1073\/pnas.122225399.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4221_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.123662","volume":"234","author":"S Khan","year":"2023","unstructured":"Khan S, et al. Osmolytes: wonder molecules to combat protein misfolding against stress conditions. Int J Biol Macromol. 2023;234:123662. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.123662.","journal-title":"Int J Biol Macromol"},{"key":"4221_CR48","doi-asserted-by":"publisher","unstructured":"Panuszko A, Bruzdziak P, Kaczkowska E, Stangret J. General mechanism of osmolytes' influence on protein stability irrespective of the type of osmolyte cosolvent. J Phys Chem B. 2016;120. https:\/\/doi.org\/10.1021\/acs.jpcb.6b10119.","DOI":"10.1021\/acs.jpcb.6b10119"},{"key":"4221_CR49","doi-asserted-by":"crossref","unstructured":"Bhattacharya M, Mukhopadhyay S. Studying protein misfolding and aggregation by fluorescence spectroscopy. 2016;1\u201327.","DOI":"10.1007\/978-3-319-24609-3_1"},{"key":"4221_CR50","doi-asserted-by":"publisher","DOI":"10.1063\/1.4811287","volume":"138","author":"H Oshima","year":"2013","unstructured":"Oshima H, Kinoshita M. Effects of sugars on the thermal stability of a protein. J Chem Phys. 2013;138:245101. https:\/\/doi.org\/10.1063\/1.4811287.","journal-title":"J Chem Phys"},{"key":"4221_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12249-012-9878-0","volume":"14","author":"M Agarkhed","year":"2013","unstructured":"Agarkhed M, et al. Effect of polysorbate 80 concentration on thermal and photostability of a monoclonal antibody. AAPS PharmSciTech. 2013;14:1\u20139. https:\/\/doi.org\/10.1208\/s12249-012-9878-0.","journal-title":"AAPS PharmSciTech"},{"key":"4221_CR52","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1021\/acs.jpcb.5b11791","volume":"120","author":"L Nicoud","year":"2016","unstructured":"Nicoud L, et al. Kinetics of monoclonal antibody aggregation from dilute toward concentrated conditions. J Phys Chem B. 2016;120:3267\u201380. https:\/\/doi.org\/10.1021\/acs.jpcb.5b11791.","journal-title":"J Phys Chem B"},{"key":"4221_CR53","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1002\/bit.23155","volume":"108","author":"M V\u00e1zquez-Rey","year":"2011","unstructured":"V\u00e1zquez-Rey M, Lang DA. Aggregates in monoclonal antibody manufacturing processes. Biotechnol Bioeng. 2011;108:1494\u2013508. https:\/\/doi.org\/10.1002\/bit.23155.","journal-title":"Biotechnol Bioeng"},{"key":"4221_CR54","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/abt\/tbac029","volume":"6","author":"W Zhang","year":"2022","unstructured":"Zhang W, et al. Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics. Antibody Ther. 2022;6:13\u201329. https:\/\/doi.org\/10.1093\/abt\/tbac029.","journal-title":"Antibody Ther"},{"key":"4221_CR55","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.jpba.2005.02.037","volume":"38","author":"SK Branch","year":"2005","unstructured":"Branch SK. Guidelines from the International Conference on Harmonisation (ICH). J Pharm Biomed Anal. 2005;38:798\u2013805. https:\/\/doi.org\/10.1016\/j.jpba.2005.02.037.","journal-title":"J Pharm Biomed Anal"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04221-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04221-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04221-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:01:49Z","timestamp":1791874909000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04221-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":55,"alternative-id":["4221"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04221-1","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"14 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}